Regeneron Pharmaceuticals, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (59)

Latest Posts

About This Stock More About This Stock
Regeneron/Sanofi's Dupixent Asthma Study Meets Endpoints
Article By: Zacks Investment Research
Monday, September 11, 2017 4:50 PM EDT
Regeneron Pharmaceuticals, Inc. and partner Sanofi announced that Dupixent (dupilumab) met its two primary endpoints in a phase III study conducted on patients with uncontrolled, persistent asthma.
In this article: SNY, REGN Also: ALXN, ADRO
Read
5 Top-Ranked Biotech Stocks To Buy Right Now
Article By: Arpita Dutt
Monday, September 11, 2017 1:09 PM EDT
Picking biotech stocks can be a bit tricky given the “high risk - high returns” nature of the industry. Moreover, the estimate revision trend for the sector is not very encouraging.
In this article: REGN, ALXN, LGND, SGMO, FATE Also: KITE, GILD
Read
How To Protect Your Money After A Tough Earnings Season
Article By: Sam Subramanian
Sunday, August 27, 2017 7:27 PM EDT
The second quarter earnings reporting season has proved to be a difficult one for stocks. The earnings reports themselves have been strong. Yet, second quarter earnings reports have been unable to lift stock prices.
In this article: HAL, HAS, REGN, NTAP
Read
4 Biotech Stocks To Add To Your Portfolio Post Q2 Earnings
Article By: Arpita Dutt
Tuesday, August 22, 2017 12:02 PM EDT
The second half of 2017 is expected to be catalyst rich for quite a few companies with data expected across a wide range of therapeutics areas.
In this article: ALXN, GILD, REGN, LGND Also: AMGN, NVS
Read
Forget Teva, Buy These 4 Drug Stocks Instead
Article By: Arpita Dutt
Friday, August 11, 2017 1:17 PM EDT
It’s not been a good quarter for Israel-based generic drug maker, Teva Pharmaceutical Industries Limited. Teva missed on both second quarter earnings and revenues and lowered its outlook for 2017.
In this article: SNY, ALXN, REGN, GILD, TEVA
Read

PARTNER HEADLINES

Latest Tweets for $REGN

No tweets yet!